v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Jun. 30, 2026
Jun. 30, 2025
OPERATING ACTIVITIES    
Net income $ 2,972,321 $ 1,900,885
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation, including amounts charged to cost of goods sold 431,959 367,582
Amortization, including amounts charged to interest expense 372,717 436,836
Provision for credit losses 6,849 45,514
Provision for deferred income taxes 247,653 4,475
Share-based compensation expense 122,789 122,020
LIFO credit (381,896) (19,913)
Türkiye highly inflationary impact 34,921 42,859
Impairment of assets, including goodwill 249,498 0
Adjustments to RCA and OneOncology equity units 152,749 74,920
Remeasurement gain related to OneOncology acquisition (Note 2) (1,086,612) 0
(Gain) loss on divestiture of businesses (17,247) 35,539
Gain on remeasurement of equity investment (4,501) (30,559)
Gain on divestiture of equity investment 0 (12,838)
Gain on sale of assets (34,768) 0
Other, net (12,755) (29,954)
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:    
Accounts receivable (754,621) (977,608)
Inventories (1,007,059) (949,881)
Prepaid expenses and other assets 161,838 237,814
Accounts payable 633,382 (61,892)
Accrued expenses (221,256) (316,650)
Income taxes payable and other liabilities (74,537) (127,446)
Long-term accrued litigation liability (103,894) 0
NET CASH PROVIDED BY OPERATING ACTIVITIES 1,687,530 741,703
INVESTING ACTIVITIES    
Capital expenditures (511,033) (418,169)
Cost of acquired companies, net of cash acquired (4,973,696) (4,004,220)
Proceeds from sale of assets 45,817 0
Proceeds from divestiture of a business 25,000 0
Cost of equity investments (28,479) (193,792)
Non-customer note receivable 23,439 (34,814)
Other, net 4,587 (4,358)
NET CASH USED IN INVESTING ACTIVITIES (5,414,365) (4,655,353)
FINANCING ACTIVITIES    
Senior notes and loan borrowings 4,687,531 4,508,482
Senior notes and loan repayments (1,069,139) (763,412)
Borrowings under revolving and securitization credit facilities 83,888,834 86,153,436
Repayments under revolving and securitization credit facilities (83,777,670) (86,120,601)
Purchases of common stock (1,000,052) (435,471)
Cash dividends on common stock (360,561) (329,569)
Employee tax withholdings related to restricted share vesting (105,324) (77,674)
Other, net (9,673) (2,295)
NET CASH PROVIDED BY FINANCING ACTIVITIES 2,253,946 2,932,896
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH (25,519) (41,800)
DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, INCLUDING CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE (1,498,408) (1,022,554)
LESS: INCREASE IN CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE (31,184) 0
DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH (1,529,592) (1,022,554)
Cash, cash equivalents, and restricted cash at beginning of period 4,394,549 3,297,880
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF PERIOD $ 2,864,957 $ 2,275,326